| Domain | Finding | Quantitative detail | Notes / clinical interpretation | Evidence |
|---|---|---:|---|---|
| Histologic share of thyroid cancer | Follicular thyroid carcinoma (FTC) is the second major differentiated thyroid carcinoma subtype but is much less common than papillary thyroid carcinoma | ~4% of thyroid cancers in one epidemiology review; ~6–10% in a 2023 pathogenesis review; ~10–15% in another recent review | Differences reflect source, classification era, and whether oncocytic/Hürthle tumors are separated; all sources agree FTC is a minority subtype of follicular-cell derived thyroid cancers | (pqac-00000000, pqac-00000004, pqac-00000011, pqac-00000012) |
| Overall thyroid cancer sex ratio | Thyroid cancer overall is markedly more common in females | ~3:1 female:male overall | FTC-specific sex ratio is less consistently quantified in the retrieved papers, but differentiated thyroid cancers including FTC follow the same female predominance pattern | (pqac-00000000, pqac-00000001, pqac-00000007, pqac-00000011) |
| Overall thyroid cancer age distribution | Incidence rises from adolescence through mid-late adulthood | Peaks around age 55 in women and 65 in men in U.S. data; mean age at diagnosis ~51 years in a 2025 review | FTC is generally an adult-onset malignancy; adverse prognosis increases with older age | (pqac-00000000, pqac-00000001, pqac-00000002) |
| Geographic distribution | Thyroid cancer incidence varies widely by region | Highest incidence reported in higher-income countries and in South Korea; also high in Canada, Italy, France, Israel, Croatia, Austria, U.S., Turkey, Brazil, Costa Rica, China, and some Pacific/island regions | Geographic variability likely reflects both diagnostic intensity/overdiagnosis and environmental exposures; FTC historically represents a larger share where iodine deficiency is more relevant | (pqac-00000000, pqac-00000001, pqac-00000011) |
| Thyroid cancer burden | Thyroid cancer is a common endocrine malignancy worldwide | ~43,800–44,000 new U.S. cases in 2022; 821,214 global cases in 2022 | FTC is a minority subset of this burden | (pqac-00000004, pqac-00000014) |
| Overall survival of differentiated thyroid carcinoma | Localized differentiated thyroid carcinoma has excellent long-term survival | 5-year survival >98% for differentiated thyroid carcinomas; 10-year survival >90% in localized disease | These figures apply to DTC broadly, including FTC; prognosis worsens substantially with distant metastases or radioiodine-refractory disease | (pqac-00000004, pqac-00000014) |
| Advanced/RAI-refractory prognosis | A minority of differentiated thyroid carcinomas become radioiodine-refractory with worse outcomes | ~5–15% develop RAI-refractory disease; median overall survival after distant metastasis/RAI-refractory disease ~2.5–3.5 years in one 2025 review | Relevant to metastatic FTC, which can lose iodine avidity and require systemic therapy | (pqac-00000014) |
| Radiation risk | Childhood exposure to ionizing radiation is the best-established modifiable thyroid cancer risk factor | Qualitatively established across reviews; no FTC-specific pooled estimate provided in retrieved texts | Radiation is classically most associated with papillary carcinoma, but is considered an established thyroid cancer risk factor overall | (pqac-00000000, pqac-00000010, pqac-00000011) |
| Iodine-related risk | Iodine deficiency is associated with follicular histology and is a recognized thyroid cancer risk context | No single pooled effect size reported in retrieved sources | FTC proportion is traditionally higher in iodine-deficient settings than in iodine-sufficient populations | (pqac-00000001, pqac-00000010) |
| Environmental/occupational risk | Environmental toxicants are plausible contributors to thyroid carcinogenesis | Reviews cite pesticides, persistent organic pollutants, phthalates, bisphenol A, PCBs, heavy metals, air pollution, and endocrine-disrupting chemicals | Evidence is stronger for thyroid cancer overall than for FTC specifically; mechanism often involves thyroid hormone disruption | (pqac-00000001, pqac-00000011) |
| Obesity and metabolic factors | Obesity is an emerging thyroid cancer risk factor | Described as an “important” or emerging risk factor in modern epidemiology reviews | Evidence is mostly for thyroid cancer overall rather than FTC alone | (pqac-00000000, pqac-00000010) |
| Family history / hereditary predisposition | Family history increases thyroid cancer risk; some hereditary syndromes predispose to follicular-cell tumors | Familial non-medullary thyroid cancer estimated at ~3–9% of thyroid cancers in one review | Hereditary syndromes relevant to follicular-patterned tumors include Cowden syndrome/PTEN-related disease and other syndromic contexts | (pqac-00000010, pqac-00000004) |
| Molecular risk background | FTC commonly arises through RAS-like molecular drivers and PI3K-pathway dysregulation | No single prevalence figure across all FTCs in retrieved excerpts; recurrent alterations include RAS mutations and PAX8-PPARG fusions | Molecular background informs classification, prognosis, and targeted-therapy strategies rather than primary prevention | (pqac-00000003, pqac-00000004, pqac-00000009) |
| Protective factors | No firmly established FTC-specific protective factors were identified in the retrieved papers | Not available | Absence of evidence in the retrieved set should not be interpreted as absence of any protective effect; rather, current literature is more focused on risk than protection | (pqac-00000000, pqac-00000011) |
| Prognostic factor: age | Older age is associated with higher risk of FTC-specific death | Age >45 years increased mortality risk in a 2023 meta-analysis | Age remains one of the strongest and most consistent prognostic variables in FTC | (pqac-00000002) |
| Prognostic factor: sex | Male sex is associated with worse FTC outcomes | Male sex increased mortality risk in FTC meta-analysis | Despite lower incidence in men, outcomes are worse when FTC occurs in males | (pqac-00000002) |
| Prognostic factor: tumor size | Larger tumors predict worse prognosis | Tumor diameter >4 cm associated with increased risk of death | Large primary tumor size is a practical adverse clinicopathologic feature | (pqac-00000002) |
| Prognostic factor: multifocality | Multifocal disease predicts worse FTC-specific survival | Associated with increased mortality risk in FTC meta-analysis | Suggests greater intrathyroidal disease burden/aggressiveness | (pqac-00000002) |
| Prognostic factor: extrathyroidal extension | Extrathyroidal extension (ETE) is adverse | ETE associated with increased risk of death | Indicates locally invasive disease | (pqac-00000002) |
| Prognostic factor: invasion pattern | Widely invasive FTC has worse outcomes than minimally invasive FTC | Widely invasive histology associated with increased mortality risk | This distinction is central to pathologic risk stratification | (pqac-00000002) |
| Prognostic factor: nodal metastasis | Cervical lymph node metastasis is adverse in FTC | CLNM associated with increased risk of death | Less common than in papillary carcinoma but prognostically unfavorable when present | (pqac-00000002) |
| Prognostic factor: distant metastasis | Distant metastasis is one of the strongest predictors of FTC mortality | DM associated with increased risk of death | Reflects FTC’s known propensity for hematogenous dissemination | (pqac-00000002) |
| Prognostic factor: surgical completeness | Non-radical resection worsens survival | Non-radical resection associated with increased mortality risk | Supports the importance of complete oncologic surgery when feasible | (pqac-00000002) |
| Distinctive clinical behavior | FTC is biologically distinct from papillary thyroid carcinoma and more prone to hematogenous spread | Qualitative | FTC has a recognized propensity for capsular and vascular invasion and distant metastasis, especially to bone/lung, which helps explain its prognostic profile | (pqac-00000002, pqac-00000007) |
| Histopathologic diagnostic hallmark | FTC diagnosis depends on invasion rather than cytology alone | Qualitative | Preoperative imaging/cytology often cannot reliably distinguish follicular adenoma from carcinoma because capsular/vascular invasion usually requires surgical pathology assessment | (pqac-00000008, pqac-00000012) |


*Table: This table summarizes the most useful epidemiologic, risk, prognostic, and survival findings for follicular thyroid carcinoma from the retrieved literature. It is designed to support rapid knowledge-base curation and highlight where data are FTC-specific versus broader differentiated thyroid cancer evidence.*